633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints

BACKGROUND: Infections caused by multidrug-resistant (MDR) bacteria are an increasingly common public health threat associated with worse outcomes in immunocompromised patients. Eravacycline (ERV) has potent in-vitro activity against MDR Gram-negative and Gram-positive bacteria and has demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunz Coyne, Ashlan J, Allosaimy, Sara, Molina, Kyle C, Kang-Birken, Lena, Lagnf, Abdalhamid M, Claeys, Kimberly C, Veve, Michael, King, Madeline, Pullinger, Benjamin, Bouchard, Jeannette, Gore, Tristan, Rojas, Leonar, Tart, Serina, Hobbs, Athena L V, Perkins, Nicholas, Biagi, Mark, Pierce, Michael, Cosimi, Reese, Jones, Bruce M, Truong, James, Andrade, Justin, Huang, Glen, Lucas, Kristen, Morrisette, Taylor, Holger, Dana, Rebold, Nicholas S, Ghali, Amer El, Davis, Susan L, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752349/
http://dx.doi.org/10.1093/ofid/ofac492.685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752349/
http://dx.doi.org/10.1093/ofid/ofac492.685

Ejemplares similares